Association of inclusion of the donor spleen in pancreaticoduodenal transplantation with rejection.
Clinical pancreas transplantation (txp) using a pancreaticoduodenal allograft (pda) and the donor spleen has been applied as treatment for insulin-dependent diabetes mellitus. Inclusion of the spleen in the pda is purported to protect against thrombosis and may be of possible immunological benefit. In pancreatectomized pigs, we compared the results of pda txp with (n = 8) and without (n = 10) the donor spleen. Animals were maintained on cyclosporine (6 mg/kg/day i.v.) and prednisolone (1.5 mg/kg/day i.v. tapered over 7 days to a maintenance dose of 0.5 mg/kg/day i.v.). Pancreatic exocrine enzyme replacement was administered daily. In 10 recipients of the technically successful pda without the spleen, rejection (blood glucose greater than 150 mg/dl) was not seen in the 28 days after txp. Mean daily blood glucose was 95 +/- 8 mg/dl during this period. In contrast, 5 of 8 recipients of the technically successful pda with the donor spleen rejected their grafts an average of 13 days (range 7-16) after txp (P less than 0.01). Mean daily blood glucose was 88 +/- 21 mg/dl prior to the declaration of rejection and increased to 275 +/- 59 mg/dl after rejection (P less than 0.0001). Rejection was histologically confirmed in all cases. None of the recipients of the pda with the donor spleen developed signs of graft-versus-host disease. Glucose tolerance testing carried out 28 days after transplantation in normoglycemic pigs from both experimental groups demonstrated no difference between the groups. In the porcine pda model used in this study, the inclusion of the spleen in the pda was associated with rejection of the transplant.
D C
DC
Dafoe
D A
DA
Campbell
W H
WH
Marks
A
A
Borgstrom
R V
RV
Lloyd
J G
JG
Turcotte
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003524:Cyclosporins / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000628:therapy; D004386:Duodenum / Q000637:transplantation*; D005951:Glucose Tolerance Test; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy; D009389:Neovascularization, Pathologic; D016035:Pancreas Transplantation; D010180:Pancreatectomy; D011239:Prednisolone / Q000627:therapeutic use; D013154:Spleen / Q000637:transplantation*; D013552:Swine; D014019:Tissue Donors; D014184:Transplantation, Homologous
D001786:Blood Glucose; D003524:Cyclosporins; D011239:Prednisolone